SMN2 and proximal spinal muscular atrophy: The potential of gene therapy in SMA was raised when a one-time intravenous administration of a self-complementary adeno-associated viral serotype 9 (scAAV9) that delivered a copy of SMN1 induced SMN expression in motor neurons and peripheral tissues, and extended the average survival in a murine model of SMA.18